HOME > ARCHIVE
ARCHIVE
- Development of Anti-obesity Drug Contrave Suspended in US
June 20, 2011
- Chuikyo to Resume Discussions on Next Round of Drug Pricing Reform on June 22
June 20, 2011
- Agensys, Seattle Genetics to Codevelop ADC ASG-22ME: Astellas
June 20, 2011
- PMDA Accelerating Preparations for Membership in PIC/S
June 20, 2011
- DSP, TRANS GENIC, Univ. of Tokyo Sign Joint Research Agreement for AIM
June 20, 2011
- Concern Growing About Gov't Plan to Revise Patients' Drug Copayments
June 20, 2011
- Fujitsu, Univ. of Tokyo to Jointly Develop Technology for Creating LMW Compounds
June 20, 2011
- Lilly Transfers Evista to Takeda in 7 Asian Markets
June 13, 2011
- Promotion Office Discussing Establishment of “Drug Discovery Support Institute”
June 13, 2011
- Prof. Kadowaki to Collect Evidence under Intensified Therapy Using Incretin-related Drugs
June 13, 2011
- Kyowa Kirin, Ferring to Copromote Desmopressin ODT for Enuresis
June 13, 2011
- Korosho to Make Unapproved Drugs under Development Available for Use
June 13, 2011
- Nippon Shinyaku to Market 3 PH Treatments Mid-decade
June 13, 2011
- Rights to PD Treatment KW-6002 in North America Returned to Kyowa Kirin
June 13, 2011
- Ono, DSP to Codevelop CTS as Additional Indication for Limaprost
June 13, 2011
- Bendamustine to Be Marketed by Eisai in South Korea: SymBio
June 13, 2011
- BMS, Roche to Collaborate in PI/II Trials of Combination Treatment for Melanoma
June 13, 2011
- 9 Companies Inaugurate Japan CSO Association on June 1
June 13, 2011
- Trisenox Launched in South Korea through BL&H: Nippon Shinyaku
June 13, 2011
- Sanofi Pasteur to Develop Single-antigen IPV in Japan
June 13, 2011
ページ
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…